Cargando…

High-soluble CGA levels are associated with poor survival in bladder cancer

Recently, a neuroendocrine-like molecular subtype has been discovered in muscle-invasive urothelial bladder cancer (BC). Chromogranin A (CGA) is a widely used tissue and serum marker in neuroendocrine tumors. Our aim was to evaluate serum CGA (sCGA) concentrations and their associations with clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Szarvas, T, Jardin-Watelet, B, Bourgoin, N, Hoffmann, M J, Nyirády, P, Oláh, C, Széll, T, Csizmarik, A, Hadaschik, B, Reis, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510714/
https://www.ncbi.nlm.nih.gov/pubmed/30999279
http://dx.doi.org/10.1530/EC-19-0068
_version_ 1783417450809786368
author Szarvas, T
Jardin-Watelet, B
Bourgoin, N
Hoffmann, M J
Nyirády, P
Oláh, C
Széll, T
Csizmarik, A
Hadaschik, B
Reis, H
author_facet Szarvas, T
Jardin-Watelet, B
Bourgoin, N
Hoffmann, M J
Nyirády, P
Oláh, C
Széll, T
Csizmarik, A
Hadaschik, B
Reis, H
author_sort Szarvas, T
collection PubMed
description Recently, a neuroendocrine-like molecular subtype has been discovered in muscle-invasive urothelial bladder cancer (BC). Chromogranin A (CGA) is a widely used tissue and serum marker in neuroendocrine tumors. Our aim was to evaluate serum CGA (sCGA) concentrations and their associations with clinical and follow-up data in BC and renal cell carcinoma (RCC). sCGA concentrations were analyzed in the following cohorts: (1) BC training set (n = 188), (2) BC validation set (n = 125), (3) RCC patients (n = 77), (4) healthy controls (n = 97). CGA immunohistochemistry and RT-qPCR analyses were performed in 20 selected FFPE and 29 frozen BC tissue samples. Acquired data were correlated with clinicopathological parameters including comorbidities with known effect on sCGA as well as with patients’ follow-up data. sCGA levels were significantly higher in BC but not in RCC patients compared to healthy controls. High sCGA levels were independently associated with poor overall and disease-specific survival both in the BC training (P < 0.001, P = 0.002) and validation set (P = 0.009, P = 0.017). sCGA levels were inversely correlated with glomerulus filtrating rate (GFR) and linearly correlated with creatinine clearance and urea concentrations. These correlations were not related to the prognostic value of sCGA. Tissue CGA levels were low to absent independently of sCGA concentrations. Our results demonstrate elevated levels and an independent prognostic value for sCGA in BC but not in RCC. Despite the significant correlation between sCGA and GFR, the prognostic relevance of sCGA seems not related to impaired renal function or other comorbidities.
format Online
Article
Text
id pubmed-6510714
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-65107142019-05-15 High-soluble CGA levels are associated with poor survival in bladder cancer Szarvas, T Jardin-Watelet, B Bourgoin, N Hoffmann, M J Nyirády, P Oláh, C Széll, T Csizmarik, A Hadaschik, B Reis, H Endocr Connect Research Recently, a neuroendocrine-like molecular subtype has been discovered in muscle-invasive urothelial bladder cancer (BC). Chromogranin A (CGA) is a widely used tissue and serum marker in neuroendocrine tumors. Our aim was to evaluate serum CGA (sCGA) concentrations and their associations with clinical and follow-up data in BC and renal cell carcinoma (RCC). sCGA concentrations were analyzed in the following cohorts: (1) BC training set (n = 188), (2) BC validation set (n = 125), (3) RCC patients (n = 77), (4) healthy controls (n = 97). CGA immunohistochemistry and RT-qPCR analyses were performed in 20 selected FFPE and 29 frozen BC tissue samples. Acquired data were correlated with clinicopathological parameters including comorbidities with known effect on sCGA as well as with patients’ follow-up data. sCGA levels were significantly higher in BC but not in RCC patients compared to healthy controls. High sCGA levels were independently associated with poor overall and disease-specific survival both in the BC training (P < 0.001, P = 0.002) and validation set (P = 0.009, P = 0.017). sCGA levels were inversely correlated with glomerulus filtrating rate (GFR) and linearly correlated with creatinine clearance and urea concentrations. These correlations were not related to the prognostic value of sCGA. Tissue CGA levels were low to absent independently of sCGA concentrations. Our results demonstrate elevated levels and an independent prognostic value for sCGA in BC but not in RCC. Despite the significant correlation between sCGA and GFR, the prognostic relevance of sCGA seems not related to impaired renal function or other comorbidities. Bioscientifica Ltd 2019-04-17 /pmc/articles/PMC6510714/ /pubmed/30999279 http://dx.doi.org/10.1530/EC-19-0068 Text en © 2019 The authors http://creativecommons.org/licenses/by-nc/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (http://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Research
Szarvas, T
Jardin-Watelet, B
Bourgoin, N
Hoffmann, M J
Nyirády, P
Oláh, C
Széll, T
Csizmarik, A
Hadaschik, B
Reis, H
High-soluble CGA levels are associated with poor survival in bladder cancer
title High-soluble CGA levels are associated with poor survival in bladder cancer
title_full High-soluble CGA levels are associated with poor survival in bladder cancer
title_fullStr High-soluble CGA levels are associated with poor survival in bladder cancer
title_full_unstemmed High-soluble CGA levels are associated with poor survival in bladder cancer
title_short High-soluble CGA levels are associated with poor survival in bladder cancer
title_sort high-soluble cga levels are associated with poor survival in bladder cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510714/
https://www.ncbi.nlm.nih.gov/pubmed/30999279
http://dx.doi.org/10.1530/EC-19-0068
work_keys_str_mv AT szarvast highsolublecgalevelsareassociatedwithpoorsurvivalinbladdercancer
AT jardinwateletb highsolublecgalevelsareassociatedwithpoorsurvivalinbladdercancer
AT bourgoinn highsolublecgalevelsareassociatedwithpoorsurvivalinbladdercancer
AT hoffmannmj highsolublecgalevelsareassociatedwithpoorsurvivalinbladdercancer
AT nyiradyp highsolublecgalevelsareassociatedwithpoorsurvivalinbladdercancer
AT olahc highsolublecgalevelsareassociatedwithpoorsurvivalinbladdercancer
AT szellt highsolublecgalevelsareassociatedwithpoorsurvivalinbladdercancer
AT csizmarika highsolublecgalevelsareassociatedwithpoorsurvivalinbladdercancer
AT hadaschikb highsolublecgalevelsareassociatedwithpoorsurvivalinbladdercancer
AT reish highsolublecgalevelsareassociatedwithpoorsurvivalinbladdercancer